AMARANTUS BIOSCIEN COM USD0.001 (AMBS)

0.04
OTC Markets
Prev Close 0.04
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.03 / 2.03
Exchange OTC Markets
Shares Outstanding 75.36B
Market Cap 3.47M
Div & Yield N.A. (N.A)

Latest News

OTCQX And OTCQB Companies To Present At 2016 Marcum MicroCap Conference

OTCQX And OTCQB Companies To Present At 2016 Marcum MicroCap Conference

OTC Markets Group, President and CEO R. Cromwell Coulson, will speak on panel "Understanding Reg A+ and the 'Mini IPO'"

Amarantus Announces Capital Infusion

Amarantus Announces Capital Infusion

Avant Diagnostics And Amarantus Diagnostics To Combine Operations With Theranostics Health

Avant Diagnostics And Amarantus Diagnostics To Combine Operations With Theranostics Health

Companies to hold a Conference Call to discuss the business combination today, March 7, 2015 at 4:30pm ET

Amarantus Announces Issuance Of Chinese Patent Covering Use Of MANF For The Treatment Of Parkinson's Disease

Amarantus Announces Issuance Of Chinese Patent Covering Use Of MANF For The Treatment Of Parkinson's Disease

Patent issuance will provide intellectual property protection in China for protein therapy, gene therapy and cell therapy applications of MANF

Amarantus Announces $1M Investment

Amarantus Announces $1M Investment

Amarantus Receives Notice Of Allowance For U.S. Patent Application Covering Method Of Treating Parkinson's Disease Levodopa-induced Dyskinesia (PD-LID)

Amarantus Receives Notice Of Allowance For U.S. Patent Application Covering Method Of Treating Parkinson's Disease Levodopa-induced Dyskinesia (PD-LID)

Patent issuance will provide additional IP protection for eltoprazine, lead product candidate, through 2027